Samsung Biologics Co Ltd
KRX:207940
Samsung Biologics Co Ltd
KRX:207940
Price:
783 000 KRW
0.26%
Updated:
May 16, 2024
P/B
Price to Book Value
Price to Book Value
5.8
Current
6.7
Median
2.6
Industry
Lower
than median
Higher
than industry value
Price to Book Value (P/B) ratio is a valuation multiple that measures the market's valuation of a company relative to its book value. The P/B ratio is only considered useful in practice when applied to capital-intensive businesses.
P/B
=5.8
Market Cap
/
55.7T
Book Value of Equity
9.5T
All Countries
| Market Cap | P/B | ||||
|---|---|---|---|---|---|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
55.7T KRW | 5.8 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
231.6B USD | 5 | |
| US |
|
Danaher Corp
NYSE:DHR
|
195.1B USD | 3.7 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
45.2B USD | 7.3 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
42.4B USD | 6.9 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
38.4B CHF | 4.1 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
32.5B USD | -204.5 | |
| IE |
|
ICON PLC
NASDAQ:ICLR
|
26.6B USD | 2.8 | |
| US |
|
West Pharmaceutical Services Inc
NYSE:WST
|
25.7B USD | 9.6 | |
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
19.8B EUR | 5.2 | |
| US |
|
Waters Corp
NYSE:WAT
|
21.5B USD | 17.1 |
P/B Forward Multiples
Forward P/B multiple is a version of the P/B ratio that uses forecasted equity for the P/B calculation. 1-Year, 2-Years, and 3-Years forwards use equity forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/B
N/A
2-Years Forward
P/B
N/A
3-Years Forward
P/B
N/A
You don't have any saved screeners yet
